<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>generative drug design - Mersad Abbasi</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        html {
            scroll-behavior: smooth;
        }

        body {
            background-color: #000000;
            color: #ffffff;
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', Arial,
                sans-serif;
            min-height: 100vh;
            padding: 3rem 2rem;
            line-height: 1.7;
        }

        .container {
            max-width: 700px;
            margin: 0 auto;
        }

        .back-link {
            display: inline-block;
            margin-bottom: 3rem;
            color: #ffffff;
            text-decoration: none;
            font-size: 0.9rem;
            font-weight: 300;
            letter-spacing: 0.05em;
            opacity: 0.7;
            transition: opacity 0.3s ease;
        }

        .back-link:hover {
            opacity: 1;
        }

        h1 {
            font-size: 2rem;
            font-weight: 300;
            letter-spacing: 0.05em;
            margin-bottom: 1rem;
            text-transform: lowercase;
        }

        .date {
            font-size: 0.9rem;
            opacity: 0.6;
            font-weight: 300;
            margin-bottom: 3rem;
        }

        .content {
            font-size: 1rem;
            font-weight: 300;
            letter-spacing: 0.01em;
        }

        .content p {
            margin-bottom: 1.5rem;
        }

        .content p:last-child {
            margin-bottom: 0;
        }

        .citation-link {
            color: #ffffff;
            text-decoration: none;
            opacity: 0.7;
            transition: opacity 0.3s ease;
            font-weight: 400;
        }

        .citation-link:hover {
            opacity: 1;
        }

        .references {
            margin-top: 4rem;
            padding-top: 3rem;
            border-top: 1px solid rgba(255, 255, 255, 0.1);
        }

        .references h2 {
            font-size: 1.5rem;
            font-weight: 300;
            letter-spacing: 0.05em;
            margin-bottom: 2rem;
            text-transform: lowercase;
        }

        .reference {
            margin-bottom: 2rem;
            padding-left: 1.5rem;
            position: relative;
        }

        .reference:last-child {
            margin-bottom: 0;
        }

        .reference-number {
            position: absolute;
            left: 0;
            font-weight: 400;
            opacity: 0.7;
        }

        .reference-title {
            font-weight: 400;
            margin-bottom: 0.3rem;
        }

        .reference-url {
            color: #ffffff;
            text-decoration: none;
            opacity: 0.6;
            font-size: 0.9rem;
            word-break: break-all;
            transition: opacity 0.3s ease;
        }

        .reference-url:hover {
            opacity: 1;
        }

        @media (max-width: 600px) {
            body {
                padding: 2rem 1.5rem;
            }

            h1 {
                font-size: 1.5rem;
            }

            .content {
                font-size: 0.95rem;
            }

            .references h2 {
                font-size: 1.2rem;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← back</a>
        <h1>generative drug design</h1>
        <div class="date">Jan 19</div>
        <div class="content">
            <p>
                Generative Drug Design, specifically one-shot or few-shot molecular design is fundementally changing how we discover drugs.
            </p>
            <p>
                Historically, drug discovery has been a search-and-verify process. Once a target
                protein, gene, or pathway is identified as causally affecting a disease, large
                chemical or biological libraries are screened to identify weak hits. These hits are
                then refined through iterative cycles of synthesis and testing. Roughly one-third of
                the drug discovery pipeline is consumed by this search phase, yet only about 1 in 250
                candidates ultimately survive to human trials <a href="#ref1" class="citation-link">[1]</a>.
            </p>
            <p>
                This workflow exists because de novo molecular design is a needle-in-a-haystack
                problem. Until recently, we either searched blindly through vast libraries or relied
                on mechanistic models that explicitly encode biophysical constraints. Foundational
                models for molecules change this paradigm. Trained on hundreds of millions to
                billions of biological sequences and related data, these models implicitly learn the
                constraints imposed by evolution and provide rich representations that can be
                leveraged for downstream molecular design.
            </p>
            <p>
                Biochemical foundation models are increasingly multimodal. By jointly modeling
                sequence, structure, function, and experiment-specific annotations, they can reason
                across modalities <a href="#ref2" class="citation-link">[2]</a>. This is especially
                important in domains like protein design, where task-specific labeled data is
                extremely scarce.
            </p>
            <p>
                Industry is already operationalizing this direction. Chai-2 reports fully de novo
                antibody design with an experimental hit rate of approximately 15–16% in a zero-shot
                setting, validated across dozens of targets <a href="#ref3" class="citation-link">[3]</a>.
                For perspective, the prior state of the art (circa 2024) achieved hit rates roughly
                two orders of magnitude lower <a href="#ref4" class="citation-link">[4]</a>. One week
                after announcing Chai-2, Eli Lilly announced a collaboration with Chai Discovery,
                under which Chai will build custom foundation models trained on Lilly’s proprietary
                data <a href="#ref5" class="citation-link">[5]</a>. This pattern is likely to
                accelerate through 2026.
            </p>
            <p>
                The next AlphaFold scale inflection point in biochemistry is approaching. Protein
                structure prediction became a compelling machine learning problem because it had (1)
                a well-defined objective, atomic coordinates, as ground truth—and (2) a clear,
                standardized evaluation framework via CASP. Protein fitness prediction, which aims
                to predict the effects of combinations of mutations, is increasingly following the
                same recipe. Benchmarks such as ProteinGym provide large, standardized datasets
                with millions of experimental measurements <a href="#ref6" class="citation-link">[6]</a>.
                Current state-of-the-art models achieve roughly 0.52 zero-shot correlation on these
                benchmarks <a href="#ref6" class="citation-link">[6]</a>. AlphaFold enabled the
                transition from sequence to structure; understanding mutation effects moves us from
                structure to function. While fitness is inherently context-dependent, this represents
                the final missing component for precise, directed de novo protein design.
            </p>
            <p>
                Drug design is fundamentally changing. Decades of wet-lab experiments and
                computational simulations generated during historical screening campaigns largely sit
                unused within large pharmaceutical companies. Tailored foundation models can unlock
                this data and compress the discovery phase from years to weeks. Startups building
                foundation-model-driven molecular design platforms are particularly well positioned,
                as they can leverage niche, high-value proprietary datasets.
            </p>
            <p>
                In the discovery phase of drug design, wet lab experimentation is expensive. One can
                bet on robotics to make this process cheaper and faster <a href="#ref7" class="citation-link">[7]</a>.
                Alternatively, one can bet on platforms that directly design molecules rather than
                search through libraries. Platforms are winning today, and we are close to a major
                breakthrough in protein fitness prediction <a href="#ref8" class="citation-link">[8]</a>
                that will make this approach even more dominant.
            </p>
        </div>

        <div class="references">
            <h2>References</h2>
            <div class="reference" id="ref1">
                <span class="reference-number">[1]</span>
                <div class="reference-title">Intuition Labs — Drug Development Timeline Explained</div>
                <a href="https://intuitionlabs.ai/articles/drug-development-timeline-explained" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://intuitionlabs.ai/articles/drug-development-timeline-explained
                </a>
            </div>
            <div class="reference" id="ref2">
                <span class="reference-number">[2]</span>
                <div class="reference-title">EvolutionaryScale — ESM-3 Release</div>
                <a href="https://www.evolutionaryscale.ai/blog/esm3-release" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://www.evolutionaryscale.ai/blog/esm3-release
                </a>
            </div>
            <div class="reference" id="ref3">
                <span class="reference-number">[3]</span>
                <div class="reference-title">Chai Discovery — De novo antibody design with Chai-2</div>
                <a href="https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf
                </a>
            </div>
            <div class="reference" id="ref4">
                <span class="reference-number">[4]</span>
                <div class="reference-title">Prior antibody design benchmarks (2024)</div>
                <a href="https://www.biorxiv.org/content/10.1101/2024.03.14.585103v1.full.pdf" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://www.biorxiv.org/content/10.1101/2024.03.14.585103v1.full.pdf
                </a>
            </div>
            <div class="reference" id="ref5">
                <span class="reference-number">[5]</span>
                <div class="reference-title">TechCrunch — From OpenAI's offices to a deal with Eli Lilly: How Chai Discovery became one of the flashiest names in AI drug development</div>
                <a href="https://techcrunch.com/2026/01/16/from-openais-offices-to-a-deal-with-eli-lilly-how-chai-discovery-became-one-of-the-flashiest-names-in-ai-drug-development/" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://techcrunch.com/2026/01/16/from-openais-offices-to-a-deal-with-eli-lilly-how-chai-discovery-became-one-of-the-flashiest-names-in-ai-drug-development/
                </a>
            </div>
            <div class="reference" id="ref6">
                <span class="reference-number">[6]</span>
                <div class="reference-title">ProteinGym — Benchmarks</div>
                <a href="https://proteingym.org/benchmarks" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://proteingym.org/benchmarks
                </a>
            </div>
            <div class="reference" id="ref7">
                <span class="reference-number">[7]</span>
                <div class="reference-title">Robot on Rails — Measuring AI's capability to accelerate biological research in the wet lab</div>
                <a href="https://robotonrails.com/measuring-ais-capability-to-accelerate-biological-research-in-the-wet-lab/" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://robotonrails.com/measuring-ais-capability-to-accelerate-biological-research-in-the-wet-lab/
                </a>
            </div>
            <div class="reference" id="ref8">
                <span class="reference-number">[8]</span>
                <div class="reference-title">Pascal Notin — Next-generation protein modeling</div>
                <a href="https://open.substack.com/pub/pascalnotin/p/next-generation-protein-modeling" class="reference-url" target="_blank" rel="noopener noreferrer">
                    https://open.substack.com/pub/pascalnotin/p/next-generation-protein-modeling
                </a>
            </div>
        </div>
    </div>
</body>
</html>
